IBI Ag has secured $10 million in Series A funding to advance its innovative bio-insecticide technology, led by Corteva and supported by multiple investors.
Information on the Target
IBI Ag is an innovative crop protection company focused on developing a diverse range of bio-insecticides that significantly reduce ecological impact. With the successful completion of its Series A funding round of $10 million, IBI Ag is poised to enhance its product development capabilities and streamline the regulatory pathways for its advanced biological pest control solutions.
Utilizing cutting-edge technology adapted from the pharmaceutical sector, IBI Ag specializes in creating biological insect control products through proprietary single-domain antibody (nanobody) methodologies. This unique approach affords significant advantages, allowing for highly selective and efficient pest management methods that safeguard valuable crops while ensuring minimal harm to non-target species.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Israel
The agricultural sector in Israel is recognized globally for its innovation and technological advancements. The country is at the forefront of agri-tech development, with a keen focus on sustainable practices that
Similar Deals
Corteva
invested in
IBI Ag
in
in a Series A deal
Disclosed details
Transaction Size: $10M